Article

Potential Utility of a 4th Generation EGFR-TKI and Exploration of Resistance Mechanisms – an In Vitro Study

2024-06-04

Abstract excerpt

The emergence of acquired resistance to EGFR-TKIs is almost inevitable even after a remarkable clinical response. Secondary mutations such as T790M and C797S are responsible for the resistance to 1st/2nd generation (1/2G) TKIs and 3G TKIs, respectively. To overcome both the T790M and C797S mutations, novel 4G EGFR-TKIs are now under early clinical development. In this study, we evaluated the efficacy of a 4G EGFR-...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: b292a76e-110c-59e9-a525-46e067634b07
DOI: 10.20944/preprints202406.0009.v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Potential Utility of a 4th Generation EGFR-TKI and Exploration of Resistance Mechanisms – an In Vitro StudyDOI 10.20944/preprints202406.0009.v1Read

Potential Utility of a 4th-Generation EGFR-TKI and Exploration of Resistance Mechanisms—An In Vitro StudySemantic proximity Read

Mechanisms and management of 3rd‑generation EGFR‑TKI resistance in advanced non‑small cell lung cancer (Review).Semantic proximity Read

Overcoming resistance to EGFR tyrosine kinase inhibitors in lung cancer, focusing on non-T790M mechanisms.Semantic proximity Read

Identification of Mutation Accumulation as Resistance Mechanism Emerging in First-Line Osimertinib Treatment.Semantic proximity Read

Characterization of the efficacies of osimertinib and nazartinib against cells expressing clinically relevant epidermal growth factor receptor mutationsSemantic proximity Read

Mechanisms of resistance to third-generation EGFR tyrosine kinase inhibitors.Semantic proximity Read

Diverse Mechanisms of Resistance against Osimertinib, a Third-Generation EGFR-TKI, in Lung Adenocarcinoma Cells with an EGFR-Activating Mutation.Semantic proximity Read

[3rd generation's TKI in lung cancer non-small cell EGFR-mutated having acquired a secondary T790M resistance].Semantic proximity Read

Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management.Semantic proximity Read

Discovery of a Novel Potent EGFR Inhibitor Against EGFR Activating Mutations and On-Target Resistance in NSCLC.Semantic proximity Read

Sequential use of EGFR-tyrosine kinase inhibitors based upon EGFR mutation evolution achieves long-term control in a non-small cell lung cancer patient: a case report.Semantic proximity Read

EAI045: The fourth-generation EGFR inhibitor overcoming T790M and C797S resistance.Semantic proximity Read